Use of magnifying lens to aid neonatal umbilical arterial catheter insertion.

We conducted this trial to test the hypothesis that use of a magnifying lens would facilitate umbilical arterial catheter (UA C) insertion in neonates. Neonates <33 weeks' gestation requiring a UA C were randomized to conventional method of catheter insertion or an experimental method using a 2.0 X magnifying lens mounted on a headband. A total of 44 neonates (Conventional = 23, Experimental = 21) with comparable demographic characteristics completed the study. The time taken for (primary outcome) and rate of successful UAC insertion (secondary outcome) were not significantly different between the two groups (median times: conventional: 88 seconds,experimental: 70 seconds, P = 0. 734) (Success rate: conventional: 19/23 (83%) vs experimental:13/21 (63%), P = 0. 1791 Thus, our hypothesis was rejected.

Pneumatosis coli, a benign form of necrotising enterocolitis.

Necrotising enterocolitis (NEC) is the most common acquired gastrointestinal emergency in neonates. Presence of pneumatosis intestinalis is taken as evidence of definite NEC. A distinctive but rare form of NEC called "pneumatosis coli" has been described, presenting with gross blood in stools and minimal or absent local and systemic signs. Radio-graph characteristically reveal isolated colonic pneumatosis without small bowel involvement. Pneumatosis coli has a more benign course compared with definite NEC. Total parenteral nutrition, antibiotics, an appropriate duration off feeds and close observation remain the corner stones of therapy assuring a benign course.

Recombinant human erythropoietin in anemia of prematurity.

OBJECTIVE: To evaluate safety and efficacy of recombinant human erythropoietin (r-HuEPO)in reducing the need for red cell transfusions in anemia of prematurity. METHODS: forty -two preterm infants (gestational age <32 weeks) were randomly assigned to a "treatment" group (r-HuEPO 400 units/kg every alternate day * 10 doses) or "no treatment" (control) group. All infants on enteral feeds received oral iron 3 mg/kg/day, graded up to 6 mg/kg/day. RESULTS: Higher reticulocyte counts in week 2 and 3 and higher hemoglobin levels in week 4 were noted after treatment with r-HuEPO. Despite stumulated erythropoiesis, the frequency of transfusions could not be reduced with r-HuEPO therapy.Overall, Phlebotomy losses, frequency and volume of redcell transfusions were significantly more in neonates with birthweight <1000 grams compared with those with birthweight >1000 grams (p<0.05). Associated side effects of r-HuEPO such as neutropenia,sepsis, hypertension or increased risk of late death did not occur. CONCLUSION:r-HuEPO therapy was safe without any side effects.Inability of r-HuEPO therapy to minimize red cell transfusions for anemia of prematurity may be explained by a relatively strict red-cell transfusion policy and the desired degree of treatment effect.